JMP Maintains Price Target and Market Outperform Rating on Evolent Health (EVH)

Evolent Health, Inc. (NYSE:EVH) is one of the top 10 healthcare AI stocks to buy according to hedge funds.

JMP Securities reaffirmed its Market Outperform rating and $13.00 price target on Evolent Health, Inc. (NYSE:EVH), highlighting a more stable and promising outlook for the company. The firm described Evolent’s current risk/reward profile as “favorably skewed,” citing a series of operational improvements and strategic shifts that have put the company on firmer footing than in recent years.

A doctor looking at their computer, discussing their patient’s care options with a group of experts.

Evolent, which provides value-based care solutions to payers and providers, has made notable progress in restructuring its risk-based arrangements and enhancing contracting mechanisms. These efforts have contributed to a healthier balance of performance obligations and upside potential. JMP noted that a strong pipeline of new business and improved visibility into existing partnerships support the firm’s bullish view. While 2025 is expected to be a trough earnings year, JMP expressed increased confidence in Evolent’s profit trajectory going forward. A key factor is the anticipated moderation in oncology-related cost trends, which have historically posed volatility in the company’s earnings profile.

Evolent Health, Inc. (NYSE:EVH) operates as a healthcare AI company, using predictive analytics and machine learning to manage complex populations, optimize clinical interventions, and reduce unnecessary costs. Its platform supports providers in making data-informed decisions, particularly in specialties like oncology and cardiology. With improved structural alignment and growing technological leverage, Evolent is well-positioned to capture long-term value in the transition to outcome-driven healthcare.

While we acknowledge the potential of EVH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EVH and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now.

Disclosure: None.